Insider Trading April 14, 2026 04:16 PM

AEHR Test Systems VP Disposes of $150k+ in Shares as Stock Nears 52-Week High

Alistair Sporck sold 2,220 shares across two transactions in April; company posts mixed Q3 fiscal 2026 results with record bookings but a revenue shortfall

By Priya Menon AEHR
AEHR Test Systems VP Disposes of $150k+ in Shares as Stock Nears 52-Week High
AEHR

Alistair N. Sporck, vice president of the Contactor Business Unit at AEHR Test Systems, reported two stock dispositions in April 2026 totaling $150,224. The filings show a 2,000-share sale on April 10 and an additional 220-share tax-related disposal on April 11. The trades come while AEHR shares trade close to a 52-week peak after a strong one-year return. Separately, AEHR reported mixed third-quarter fiscal 2026 results, beating EPS estimates but missing revenue expectations, while recording record quarterly bookings and a backlog above $50 million.

Key Points

  • Alistair N. Sporck sold 2,000 AEHR shares on April 10, 2026 at $67.365 per share for $134,730, and an additional 220 shares on April 11, 2026 at $70.43 per share for $15,494, according to an SEC Form 4.
  • Following the sales, Sporck directly owns 22,635 shares (including unvested restricted stock units) and indirectly owns 7,177 shares through a trust.
  • AEHR reported mixed fiscal Q3 2026 results: EPS of -$0.05 beat estimates of -$0.07, revenue of $10.3 million slightly missed the $10.8 million consensus, and the company recorded record quarterly bookings of $37.2 million with a backlog above $50 million; several analysts raised price targets.

Insider sales disclosed

Alistair N. Sporck, who serves as vice president of the Contactor Business Unit at AEHR TEST SYSTEMS (NASDAQ:AEHR), sold 2,000 shares of the company's common stock on April 10, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a per-share price of $67.365, producing proceeds of $134,730.

The filing also shows that Sporck disposed of an additional 220 shares on April 11, 2026, at $70.43 per share. That second transaction, identified in the filing as covering tax obligations, totaled $15,494.


Post-transaction holdings

After these transactions, Sporck is reported to directly hold 22,635 shares of AEHR Test Systems common stock. That direct holding figure includes shares that remain subject to unvested restricted stock units. In addition to direct ownership, Sporck is listed as indirectly owning 7,177 shares through a trust.


Market context and valuation note

The insider sales occurred while AEHR shares trade near a 52-week high of $74.53, following a reported one-year return of 763%. An InvestingPro analysis cited in the filing commentary characterizes the stock as appearing overvalued at current levels.


Recent financial results

In other company disclosures, Aehr Test Systems reported mixed financial results for the third quarter of fiscal 2026. The company posted earnings per share of -$0.05, which was ahead of the analyst consensus of -$0.07. Revenue for the quarter was $10.3 million, marginally below the consensus estimate of $10.8 million.

Despite the revenue shortfall, the company reported record quarterly bookings of $37.2 million, and a backlog that the company says exceeds $50 million. Those booking metrics have prompted several analysts to lift price targets: Freedom Broker raised its target to $61 while keeping a Hold rating, and Lake Street increased its target to $56 while maintaining a Buy rating. Analysts cited the bookings strength in explaining their revised targets, and their guidance adjustments reflect a positive view even as revenue lagged estimates.


What is clear

The filings provide a transparent record of Sporck's April dispositions and a snapshot of AEHR's most recent quarter - a mix of upside in EPS and bookings, and a slight revenue miss. The company remains positioned with a sizeable backlog and has drawn valuation scrutiny from market commentators.

Risks

  • Valuation concern: An InvestingPro analysis cited in disclosures characterizes the stock as appearing overvalued at current levels, which could affect investor sentiment and market pricing.
  • Revenue shortfall versus consensus: Quarterly revenue of $10.3 million was slightly below the $10.8 million estimate, indicating a near-term revenue execution risk despite stronger EPS and bookings.
  • Market sensitivity to insider activity and price levels: The insider disposals occurred while the share price was trading near a 52-week high, a combination that may increase attention to share price volatility in the semiconductor equipment and capital markets sectors.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026